Latest news with #ResmedInc
Business Insider
22-07-2025
- Business
- Business Insider
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Receives a Buy from Jarden
In a report released on July 18, Steven Wheen from Jarden maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per with a price target of A$40.55. The company's shares opened today at A$39.85. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Wheen is a 4-star analyst with an average return of 17.5% and a 58.95% success rate. Wheen covers the Healthcare sector, focusing on stocks such as CSL, Healius Limited, and Ramsay Health Care. Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per has an analyst consensus of Strong Buy, with a price target consensus of A$44.80.
Business Insider
23-05-2025
- Business
- Business Insider
Goldman Sachs Sticks to Its Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)
Goldman Sachs analyst Davinthra Thillainathan maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per (RMD – Research Report) on May 20 and set a price target of A$49.30. The company's shares closed today at A$38.24. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Thillainathan covers the Healthcare sector, focusing on stocks such as Ramsay Health Care, CSL, and Cochlear . According to TipRanks, Thillainathan has an average return of 3.7% and a 75.00% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per with a A$44.69 average price target.
Business Insider
21-05-2025
- Business
- Business Insider
Morgan Stanley Sticks to Their Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)
In a report released today, David Bailey from Morgan Stanley maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per (RMD – Research Report). The company's shares opened today at A$38.62. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Bailey is a 4-star analyst with an average return of 17.4% and a 49.02% success rate. Bailey covers the Healthcare sector, focusing on stocks such as CSL, Resmed, and Ansell. Currently, the analyst consensus on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per is a Strong Buy with an average price target of A$44.59. Based on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of A$1.29 billion and a net profit of A$365.04 million. In comparison, last year the company earned a revenue of A$1.2 billion and had a net profit of A$300.49 million
Business Insider
12-05-2025
- Business
- Business Insider
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from UBS
In a report released today, Marcus Curley from UBS maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per (RMD – Research Report). The company's shares opened today at A$38.26. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Curley is an analyst with an average return of -13.2% and a 42.67% success rate. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per with a A$44.59 average price target. The company has a one-year high of A$40.75 and a one-year low of A$27.13. Currently, Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per has an average volume of 1.4M.
Business Insider
05-05-2025
- Business
- Business Insider
UBS Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)
UBS analyst Marcus Curley maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per (RMD – Research Report) today. The company's shares opened today at A$37.29. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Curley is an analyst with an average return of -14.0% and a 41.10% success rate. In addition to UBS, Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per also received a Buy from Morgan Stanley's David Bailey in a report issued on April 28. However, on April 24, Wilsons maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per (ASX: RMD). Based on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of A$1.29 billion and a net profit of A$365.04 million. In comparison, last year the company earned a revenue of A$1.2 billion and had a net profit of A$300.49 million
